Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia

References

• SwerdlowSCampoEHarrisNLWHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (IARC WHO Classification of Tumours)4th edGenevaWorld Health Organization2008
   Google Scholar
• StockWJohnsonJLStoneRMDose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Cancer20131191909822744771
   PubMed Web of Science ®Google Scholar
• ThomasDAO’BrienSFaderlSChemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemiaJ Clin Oncol201028243880388920660823
   PubMed Web of Science ®Google Scholar
• BrüggemannMRaffTFlohrTClinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaBlood200610731116112316195338
   PubMed Web of Science ®Google Scholar
• FieldingAKRichardsSMChopraROutcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ ECOG 2993 studyBlood2007109394495017032921
   PubMed Web of Science ®Google Scholar
• PaiettaELiXRichardsSImplications for the use of monoclonal antibodies in future adult ALL Trials: analysis of antigen expression in 505 B-lineage (B-lin) ALL patients (pts) on the MRC UKALLXII/ ECOG2993 intergroup trialASH Annu Meet Abstr20081121907
   Google Scholar
• RaponiSDe ProprisMSIntoppaSFlow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 casesLeuk Lymphoma20115261098110721348573
   PubMed Web of Science ®Google Scholar
• NagorsenDKuferPBaeuerlePABargouRBlinatumomab: a historical perspectivePharmacol Ther2012136333434222940266
   PubMed Web of Science ®Google Scholar
• GabrilovichDPisarevVTumor escape from immune response: mechanisms and targets of activityCurr Drug Targets20034752553614535653
   PubMed Web of Science ®Google Scholar
• KozmikZWangSDörflerPAdamsBBusslingerMThe promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAPMol Cell Biol1992126266226721375324
   PubMed Web of Science ®Google Scholar
• StamenkovicISeedBCD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tailJ Exp Med19881683120512102459292
   PubMed Web of Science ®Google Scholar
• TedderTFIsaacsCMIsolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamilyJ Immunol198914327127172472450
   PubMed Web of Science ®Google Scholar
• ZhouLJOrdDCHughesALTedderTFStructure and domain organization of the CD19 antigen of human, mouse, and guinea pig B lymphocytes. Conservation of the extensive cytoplasmic domainJ Immunol19911474142414321714482
   PubMed Web of Science ®Google Scholar
• NagorsenDBaeuerlePAImmunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomabExp Cell Res201131791255126021419116
   PubMed Web of Science ®Google Scholar
• CarterRHTuvesonDAParkDJRheeSGFearonDTThe CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complexJ Immunol199114711366336711719083
   PubMed Web of Science ®Google Scholar
• FujimotoMFujimotoYPoeJCCD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplificationImmunity2000131475710933394
   PubMed Web of Science ®Google Scholar
• van ZelmMCReisliIvan der BurgMAn antibody-deficiency syndrome due to mutations in the CD19 geneN Engl J Med2006354181901191216672701
   PubMed Web of Science ®Google Scholar
• UckunFMSunLQaziSMaHOzerZRecombinant human CD19-ligand protein as a potent anti-leukaemic agentBr J Haematol20111531152321323891
   PubMed Web of Science ®Google Scholar
• LandmeierSAltvaterBPschererSCytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivoLeukemia20102451080108420220773
   PubMed Web of Science ®Google Scholar
• PressOWFarrAGBorrozKIAndersonSKMartinPJEndocytosis and degradation of monoclonal antibodies targeting human B-cell malignanciesCancer Res19894917490649122667754
   PubMed Web of Science ®Google Scholar
• Stanciu-HerreraCMorganCHerreraLAnti-CD19 and anti- CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell linesLeuk Res200832462563217706771
   PubMed Web of Science ®Google Scholar
• GhetieMAGhetieVVitettaESAnti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cellsClin Cancer Res19995123920392710632321
   PubMed Web of Science ®Google Scholar
• GhetieMAPickerLJRichardsonJATuckerKUhrJWVitettaESAnti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrestBlood1994835132913367509655
   PubMed Web of Science ®Google Scholar
• BarachoGVMileticAVOmoriSACatoMHRickertRCEmergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiationCurr Opin Immunol201123217818321277760
   PubMed Web of Science ®Google Scholar
• BargouRLeoEZugmaierGTumor regression in cancer patients by very low doses of a T cell-engaging antibodyScience2008321589197497718703743
   PubMed Web of Science ®Google Scholar
• BrischweinKParrLPflanzSStrictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE classJ Immunother200730879880718049331
   PubMed Web of Science ®Google Scholar
• ThakurALumLGCancer therapy with bispecific antibodies: clinical experienceCurr Opin Mol Ther201012334034920521223
   PubMedGoogle Scholar
• HoffmannPHofmeisterRBrischweinKSerial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody constructInt J Cancer200511519810415688411
   PubMed Web of Science ®Google Scholar
• DreierTLorenczewskiGBrandlCExtremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibodyInt J Cancer2002100669069712209608
   PubMed Web of Science ®Google Scholar
• LöfflerAKuferPLutterbüseRA recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma- directed cytotoxicity by unstimulated T lymphocytesBlood20009562098210310706880
   PubMed Web of Science ®Google Scholar
• OffnerSHofmeisterRRomaniukAKuferPBaeuerlePAInduction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cellsMol Immunol200643676377116360021
   PubMed Web of Science ®Google Scholar
• LöfflerAGruenMWuchterCEfficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody constructLeukemia200317590090912750704
   PubMed Web of Science ®Google Scholar
• BrandlCHaasCd’ArgougesSThe effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody constructCancer Immunol Immunother200756101551156317310380
   PubMed Web of Science ®Google Scholar
• DreierTBaeuerlePAFichtnerIT cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/ CD3-bispecific single-chain antibody constructJ Immunol200317084397440212682277
   PubMed Web of Science ®Google Scholar
• KlingerMBrandlCZugmaierGImmunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomabBlood2012119266226623322592608
   PubMed Web of Science ®Google Scholar
• ToppMSGoekbugetNZugmaierGAnti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs overall survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)ASH Annu Meet Abstr2012120670
   Google Scholar
• ToppMSGökbugetNZugmaierGLong-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLBlood2012120265185518723024237
   PubMed Web of Science ®Google Scholar
• ToppMSKuferPGökbugetNTargeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survivalJ Clin Oncol201129182493249821576633
   PubMed Web of Science ®Google Scholar
• ChesonBDPfistnerBJuweidMERevised response criteria for malignant lymphomaJ Clin Oncol200725557958617242396
   PubMed Web of Science ®Google Scholar